
The ORION-3 study explored the efficacy and safety of inclisiran, an injectable therapy targeting PCSK9, in lowering LDL cholesterol levels. Over four years, the study showed sustained LDL reductions by around 44%, with minimal adverse events. Inclisiran's twice-yearly dosing proved feasible and convenient, making it a promising option to manage high LDL cholesterol in high-risk patients, complementing oral medications.
Like
Save
Share